• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by XORTX Therapeutics Inc.

    2/14/25 5:04:07 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XRTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    XORTX Therapeutics Inc.

    (Name of Issuer)


    Common shares, no par value per share

    (Title of Class of Securities)


    98420Q306

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    98420Q306


    1Names of Reporting Persons

    Armistice Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    346,807.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    346,807.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    346,807.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    98420Q306


    1Names of Reporting Persons

    Steven Boyd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    346,807.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    346,807.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    346,807.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    XORTX Therapeutics Inc.
    (b)Address of issuer's principal executive offices:

    SUITE 2400 - 745 THURLOW STREET, VANCOUVER, British Columbia, Canada, V6E 0C5
    Item 2. 
    (a)Name of person filing:

    Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
    (b)Address or principal business office or, if none, residence:

    Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
    (c)Citizenship:

    Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
    (d)Title of class of securities:

    Common shares, no par value per share
    (e)CUSIP No.:

    98420Q306
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    346,807
    (b)Percent of class:

    9.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    346,807

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    346,807 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Armistice Capital, LLC
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd - Managing Member
    Date:02/14/2025
     
    Steven Boyd
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd
    Date:02/14/2025
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

    Get the next $XRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XRTX

    DatePrice TargetRatingAnalyst
    12/9/2021$11.00Buy
    Alliance Global Partners
    More analyst ratings

    $XRTX
    Financials

    Live finance-specific insights

    See more
    • XORTX Announces Date for Rescheduled Special Meeting of Shareholders

      CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. (Calgary time) on Friday, October 27, 2023 (the "Meeting"). At the Meeting shareholders will consider a consolidation of the Company's issued and outstanding shares in order for the Company to regain compliance with the continued listing requirements for the NASDAQ Capital Market. About XORTX Therap

      10/25/23 5:00:00 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Therapeutics Announces Annual and Special Meeting of Shareholders

      CALGARY, Alberta, Nov. 23, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (TSXV:XRTX, NASDAQ:XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces that it will hold its annual and special meeting of shareholders at 11:00 a.m. (Calgary time) on Monday, December 20, 2021 (the "Meeting"). Materials for the Meeting have been mailed to shareholders and are available on the Company's SEDAR profile and the Company's website. The meeting has been called for shareholders to consider annual matters including the election of directors, re-appointment of Smythe LLP Chartered Accountants as au

      11/23/21 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by XORTX Therapeutics Inc. (Amendment)

      SC 13G/A - XORTX Therapeutics Inc. (0001729214) (Subject)

      2/14/24 3:03:47 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by XORTX Therapeutics Inc.

      SC 13G - XORTX Therapeutics Inc. (0001729214) (Subject)

      2/14/23 1:48:46 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • XORTX Announces Results of Annual and Special Meeting of Shareholders

      CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the "Meeting") held Thursday, September 12, 2024. A total of 889,288 common shares of the Company were represented at the Meeting, representing approximately 31% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including electi

      9/13/24 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

      4/8/24 7:30:00 AM ET
      $GMDA
      $XRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • XORTX Announces New Clinical Advisory Board Member

      CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease ("ADPKD"), is pleased to announce that Dr. Ronald Perrone has joined the Company's Clinical Advisory Board. Dr. Allen Davidoff stated, "We are excited that Dr. Ron Perrone has agreed to join XORTX's Clinical Advisory Board. Dr. Perrone brings substantial medical and professional experience as a thought leader, combined with clinical experience treating patients with ADPKD and kidney disease. We are privileged

      3/27/24 5:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XRTX
    SEC Filings

    See more
    • SEC Form NT 20-F filed by XORTX Therapeutics Inc.

      NT 20-F - XORTX Therapeutics Inc. (0001729214) (Filer)

      5/1/25 7:00:29 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by XORTX Therapeutics Inc.

      6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

      4/30/25 7:00:09 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by XORTX Therapeutics Inc.

      6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

      4/28/25 7:00:07 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • XORTX Provides Update on FDA Type B Meeting Request

      ● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the "FDA") and clarified key steps for a new drug application ("NDA") for the Company's novel proprietary formulation of oxypurinol for the treatment of gout. The Type B meeting conducted by the FDA, included review of chemistry, manufacturing, ph

      4/30/25 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Announces Grant of European Patent

      CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease , is pleased to announce receipt of notification that the patent "Xanthine Oxidase Inhibitor Formulations" will be granted by the European Patent Office. The patent covers compositions and methods of formulating using XORTX's proprietary formulations of xanthine oxidase inhibitors ("XOI") for the treatment of health consequences of chronically high uric acid, gout, renal, cardiovascular and other diseases where abe

      4/28/25 7:00:00 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

      CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.

      4/17/25 7:45:00 PM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on XORTX Therapeutics with a new price target

      Alliance Global Partners initiated coverage of XORTX Therapeutics with a rating of Buy and set a new price target of $11.00

      12/9/21 9:10:32 AM ET
      $XRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care